KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacira BioSciences (PCRX) EBT (2016 - 2026)

Pacira BioSciences has reported EBT over the past 17 years, most recently at $5.0 million for Q1 2026.

  • For Q1 2026, EBT fell 42.59% year-over-year to $5.0 million; the TTM value through Mar 2026 reached $13.2 million, up 119.35%, while the annual FY2025 figure was $16.9 million, 126.74% up from the prior year.
  • EBT for Q1 2026 was $5.0 million at Pacira BioSciences, up from $571000.0 in the prior quarter.
  • Over five years, EBT peaked at $37.9 million in Q2 2023 and troughed at -$138.9 million in Q3 2024.
  • A 5-year average of $2.0 million and a median of $8.7 million in 2025 define the central range for EBT.
  • Biggest five-year swings in EBT: surged 702.37% in 2023 and later plummeted 936.43% in 2024.
  • Year by year, EBT stood at -$18.1 million in 2022, then surged by 286.63% to $33.7 million in 2023, then dropped by 24.3% to $25.5 million in 2024, then plummeted by 97.76% to $571000.0 in 2025, then soared by 775.31% to $5.0 million in 2026.
  • Business Quant data shows EBT for PCRX at $5.0 million in Q1 2026, $571000.0 in Q4 2025, and $9.5 million in Q3 2025.